93 related articles for article (PubMed ID: 30959047)
41. Direct inhibitory effect of flaxseed on porcine ovarian granulosa cell functions.
Štochmal'ová A; Harrath AH; Alwasel S; Sirotkin AV
Appl Physiol Nutr Metab; 2019 May; 44(5):507-511. PubMed ID: 30286297
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
43. Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway.
Wang Y; Chen J; Tang W; Zhang Y; Li X
Biomed Pharmacother; 2017 Jan; 85():272-279. PubMed ID: 27914823
[TBL] [Abstract][Full Text] [Related]
44. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
45. mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Wesierska-Gadek J
Aging (Albany NY); 2010 Dec; 2(12):892-3. PubMed ID: 21149896
[No Abstract] [Full Text] [Related]
46. Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP‑activated protein kinase/mammalian target of rapamycin autophagy signaling pathway.
Liu Q; Fang Q; Ji S; Han Z; Cheng W; Zhang H
Mol Med Rep; 2018 Jan; 17(1):502-508. PubMed ID: 29115429
[TBL] [Abstract][Full Text] [Related]
47. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
48. Sirtuin 1 independent effects of resveratrol in INS-1E β-cells.
Erdogan CS; Mørup-Lendal M; Dalgaard LT; Vang O
Chem Biol Interact; 2017 Feb; 264():52-60. PubMed ID: 28108221
[TBL] [Abstract][Full Text] [Related]
49. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
50. mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro.
McLaughlin M; Patrizio P; Kayisli U; Luk J; Thomson TC; Anderson RA; Telfer EE; Johnson J
Fertil Steril; 2011 Nov; 96(5):1154-9.e1. PubMed ID: 22036052
[TBL] [Abstract][Full Text] [Related]
51. Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation.
Zhao Y; Zhao MM; Cai Y; Zheng MF; Sun WL; Zhang SY; Kong W; Gu J; Wang X; Xu MJ
Kidney Int; 2015 Oct; 88(4):711-21. PubMed ID: 26061549
[TBL] [Abstract][Full Text] [Related]
52. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
53. Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.
Rogers-Broadway KR; Kumar J; Sisu C; Wander G; Mazey E; Jeyaneethi J; Pados G; Tsolakidis D; Klonos E; Grunt T; Hall M; Chatterjee J; Karteris E
Int J Mol Med; 2019 Jan; 43(1):47-56. PubMed ID: 30387804
[TBL] [Abstract][Full Text] [Related]
54. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Alayev A; Salamon RS; Schwartz NS; Berman AY; Wiener SL; Holz MK
J Cell Physiol; 2017 Feb; 232(2):436-446. PubMed ID: 27225870
[TBL] [Abstract][Full Text] [Related]
55. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
56. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
57. 3,4-Dimethoxystilbene, a resveratrol derivative with anti-angiogenic effect, induces both macroautophagy and apoptosis in endothelial cells.
Zhang L; Jing H; Cui L; Li H; Zhou B; Zhou G; Dai F
J Cell Biochem; 2013 Mar; 114(3):697-707. PubMed ID: 23059970
[TBL] [Abstract][Full Text] [Related]
58. Effect of dual mTOR inhibitor on TGFβ1-induced fibrosis in primary human urethral scar fibroblasts.
Huang S; Yang C; Li M; Wang B; Chen H; Fu D; Chong T
Biomed Pharmacother; 2018 Oct; 106():1182-1187. PubMed ID: 30119186
[TBL] [Abstract][Full Text] [Related]
59. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
60. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
